Earnings call transcript: Precision Optics sees 108% revenue growth in Q3 2026

Precision Optics reported record Q3 FY2026 revenue of $8.7 million, up 108% year over year, and turned adjusted EBITDA positive at $300,000 versus a $1.3 million loss a year ago. Gross margin expanded to 23.6% from 10%, cash rose to $10.7 million after an oversubscribed $10 million offering, and full-year revenue guidance was raised to $29 million-$31 million. The company also highlighted strong aerospace and cystoscope program momentum, though aerospace volumes are expected to dip 15%-20% in Q1-Q2 FY2027 due to customer slowdown.

Analysis

The key second-order read is that POCI is no longer just a revenue story; it is becoming an operating leverage story with optionality. The combination of higher yields, steadier throughput, and a larger installed base of production lines should make incremental revenue in the next 2-3 quarters disproportionately accretive to EBITDA, especially if Ross Optical keeps contributing higher-mix volume. That said, the business is still exposed to a few concentrated programs, so the market is likely to start valuing execution quality and backlog conversion more than headline growth.

The aerospace slowdown is not a thesis-breaker, but it does create a near-term air pocket that could mask the underlying inflection. The bigger issue is that management is signaling demand timing risk from the customer side, not manufacturing-side weakness; that usually means the stock can stay bid until the market realizes the revenue bridge into Q1/Q2 is noisier than the quarterly print suggests. In other words, the upside is likely front-loaded on confirmation of margin durability, while the downside is deferred but sharper if the backlog normalization slips.

The most interesting hidden catalyst is the licensing/royalty pathway in the single-use programs. If customer-site duplication expands, POCI can effectively turn one account into a multi-site annuity without a linear SG&A buildout, which is much more valuable than a simple unit shipment model. The market may be underestimating how quickly that can re-rate the earnings power if the Unity pipeline starts converting: even a handful of $1M-$3M production programs would materially change the revenue mix over 12 months.

Contrarian view: the move may be somewhat overdone if investors extrapolate the current quarter as a clean run-rate. A meaningful chunk of the gross margin step-up was aided by favorable one-offs and tariff mechanics, while the true test is whether yield gains persist once the aerospace pause and cystoscope transition work through the system. If they do, this becomes a compounding story; if they don’t, the current optimism could fade into a low-quality growth trap.

Key Decisions for Investors

• Long POCI common on weakness over the next 2-4 weeks; target a 3-6 month hold. Thesis is operating leverage plus balance-sheet de-risking, but size modestly because revenue concentration makes quarter-to-quarter volatility high.
• Buy POCI Jan/Apr 2027 call spreads to express the multi-quarter margin inflection without paying full equity downside; best entry is on any post-earnings pullback or if the stock gives back the initial enthusiasm.
• Pair trade: long POCI / short a basket of lower-quality medtech microcaps with no clear margin inflection. The relative value is strongest if POCI continues printing positive EBITDA while peers remain cash-burn stories.
• Trim or hedge if management commentary starts implying the aerospace pullback extends beyond Q2 FY2027; that would turn a temporary timing issue into a backlog digestion problem and compress the multiple.
• Monitor Unity conversion as the key catalyst; if 2+ of the 4 active prospects move into engineering within the next 1-2 quarters, add to longs because that would validate the platform as a pipeline accelerator rather than just a marketing concept.